Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBlue Cross Blue Shield - Oklahoma Drug List Covera…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentBlue Cross Blue Shield - OklahomaPolicy N/A

    2025 Drug List (Pharmacy Benefit) — Coverage Criteria

    Customize your policy alerts

    Sign up for all Blue Cross Blue Shield - Oklahoma policy alerts

    Know when Blue Cross Blue Shield - Oklahoma releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines the pharmacy drug list (covered drugs, tiers, special requirements, and processes) for Blue Cross and Blue Shield of Oklahoma members and their prescribing providers; applies to drugs covered under the pharmacy benefit and guidance on specialty drugs, prior authorization, step therapy, quantity limits, and exceptions.

    Policy Summary
    PayerBlue Cross Blue Shield - Oklahoma
    PolicyCoverage criteria for the 2025 Drug List (Pharmacy Benefit)
    Policy CodePolicy N/A
    Change TypeNo material changes (routine update)
    Effective DateN/A
    Next Review DateN/A
    Key ActionObtain prior authorization and submit supporting documentation for drugs marked 'PA' before dispensing.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    ~150+drug entries (partial)
    Manyentries with PA/QL/SP
    QL presentquantity limits present
    vaccines includedvaccines with AC
    6member payment tiers

    Coverage Criteria & Formulary Listing

    Pharmacy benefit coverage general criteria

    Covered when ALL of the following are met

    coverage_baseline: Drug is listed on the 2025 Drug List or an approved exception exists

    Drugs not shown on the drug list are not covered unless an exception is approved

    FDA_approval: Drug has FDA approval when required for coverage; non-FDA-approved drugs are not covered

    Non‑FDA‑approved drugs are not covered per plan guidance

    benefit_specific_limits: Coverage is subject to the member's benefit plan limits including tiering, quantity limits (QL), dispensing limits (30‑day standard; some 90‑day maintenance), and site‑of‑care rulessee plan materials

    Refer to individual plan materials or MyPrime.com for specifics

    Policy Summary
    PayerBlue Cross Blue Shield - Oklahoma
    PolicyCoverage criteria for the 2025 Drug List (Pharmacy Benefit)
    Policy CodePolicy N/A
    Change TypeNo material changes (routine update)
    Effective DateN/A
    Next Review DateN/A
    Key ActionObtain prior authorization and submit supporting documentation for drugs marked 'PA' before dispensing.
    SourceLink
    On This Page
    Coverage Criteria & Formulary ListingCoding, Quantity Examples & LimitsProvider Actions — Prior Authorization, Step Therapy, DocumentationInitiation & Initial Dispensing ControlsStep Therapy — Presence and ExamplesQuantity Limits — Product ExamplesSite of Care & Specialty PharmacyDefinitions & NotationBackground & Scope

    General coverage constraints

    Coverage and dispensing subject to listed requirement flags and quantity limits

    Formulary_coverage_constraints: Drug is covered according to its formulary tier but may require prior authorization (PA), be subject to a quantity limit (QL), or require specialty pharmacy (SP) dispensing as indicated next to each productsee per‑product QL values

    Examples in the drug list: HARVONI (PA, QL 30 tablets/30 days, SP); ISENTRESS (QL 60 tablets/30 days); MAVYRET pellet pack (PA, QL) and VOSEVI (PA, QL 30 tablets/30 days, SP).

    Formulary listing with utilization management codes

    Coverage stance is conveyed via Drug Tier and Requirements/Limits entries for each listed product

    Formulary_entries_with_flags: Each listed product line includes a Drug Tier value and a Requirements/Limits code (e.g., AC, PA, QL, SP, NP, P) that determine coverage and management actions

    This section presents per‑product annotations; no additional clinical decision logic is embedded in these entries.

    Formulary entries with product-specific requirements

    Drugs are listed with tier and specific Requirements/Limits; coverage depends on those annotations.

    Examples_of_product_specific_requirements: Formulary entries include product‑specific Requirements/Limits such as AC, PA, QL, and SP; examples: MENOSTAR patch (QL 30 patches/30 days); ORIAHNN pack (PA, QL 56 capsules/28 days); ANNOVERA ring (AC, QL 1 ring/365 days); many oral contraceptives (AC, QL 28 tablets/21 days); MOUNJARO (PA, QL 4 pens/28 or 180 days depending on presentation); OZEMPIC (PA, QL 1 pen/28 days or specified mL limits); RYBELSUS (PA, QL 30 tablets/30 or 180 days depending on strength).see individual product lines

    Coverage and any PA/QL/AC indicated per product lines in the drug list

    Formulary coverage listing

    Coverage and management by product/formulation as listed

    Formulary_listing_catalog: Each drug/formulation line includes Drug Tier and Requirements/Limits fields indicating coverage stance (e.g., P, NP, NP+, NPT) and management codes (PA, QL, SP).

    This content set is a formulary catalog; medical necessity criteria beyond the listed annotations are not provided in these chunks.

    Coverage for pharmacy benefit drugs is determined by whether the product is included on the payer's Drug List or has an approved exception. The plan may not cover drugs not shown on the Drug List. In addition, the plan's benefit materials note that over-the-counter equivalents, compounded medications, repackaged medications, and non–FDA‑approved drugs may not be covered; providers and members should refer to the member's specific benefit plan or call the number on the ID card for clarification or to request an exception.

    The extracted formulary segments are presented as product listings with Drug Tier and Requirements/Limits flags; they do not contain a separate exclusions section. In other words, within the cited chunks there are no explicit exclusions listed — non‑coverage is primarily implied when a drug is absent from the Drug List rather than by named exclusion rules in these chunks.

    The document excerpts show product lines annotated with tier and requirement flags but do not contain separate clinical exclusion rules in the cited chunks. There are no explicit clinical exclusions stated in these chunks; coverage limitations are conveyed by per‑product annotations such as PA, QL, SP, or AC rather than by standalone clinical exclusion statements.

    The listed entries in these chunks are formulary lines with Drug Tier and Requirements/Limits annotations. They do not set out clinical coverage criteria (for example, specific diagnosis, prior‑therapy failure, or lab thresholds). Therefore, in the cited material there are no explicit clinical coverage criteria

    The document extract conveys coverage stance via Drug Tier and Requirements/Limits fields and per‑product QL/PA/SP annotations, but it does not include a medical‑necessity decision algorithm in these chunks. There are no explicit medical necessity criteria described here; providers should follow the PA process and supply supporting clinical documentation when a PA is required.

    Dispensing and quantity limits are enforced at claim adjudication. The plan notes that dispensed quantities beyond stated dispensing/quantity limits may be denied, and for certain controlled substances state law may prohibit coverage if the dispensed quantity exceeds the limit; in such cases the member would be responsible for the full cost of the excess medication. Providers should confirm per‑product QL values and follow prior authorization procedures when requesting quantities beyond listed limits.

    Within the cited chunks there are no lines that explicitly state 'not medically necessary' determinations for specific clinical scenarios. The document communicates management via per‑product flags (e.g., PA, QL, SP) but does not include named 'not medically necessary' rulings in these excerpts.

    The segments reviewed do not list specific conditions or situations labeled as 'not medically necessary.' Coverage is determined by whether a drug is on the Drug List and by the product's Requirements/Limits entries; explicit non‑medical‑necessity statements are not present in these chunks.

    Coding, Quantity Examples & Limits

    NDC/CPT/HCPCS not listedmixed
    No codes listed
    No CPT/HCPCS/ICD-10 codes listed in these chunksmixed
    No codes listed
    inv-16: Quantity Limits examples
    Examples of per-product QL formatsCommon quantity-limit formats shown in the Drug List include: e.g., 30 tablets/30 days; 60 tablets/30 days; 4 bottles/30 days; 126 tablets/365 days
    Use at dispensingQuantity limits are enforced at the pharmacy benefit and expressed as a numeric limit plus a time period (e.g., QL (30 tablets/30 days)).
    Associated flagsProducts with QL entries are frequently also marked PA and/or SP indicating prior authorization or specialty pharmacy requirements may apply.
    inv-17: Example quantity limits
    Contraceptive QL examplesExamples include 28 tablets/21 days (oral contraceptives), 3 patches/21 days (transdermal), 1 ring/365 days (ANNOVERA).
    GLP‑1 / weight‑management QL examplesExamples include 4 pens/28 days or 4 pens/180 days for certain tirzepatide/semaglutide products (MOUNJARO, WEGOVY).
    Other package QLsPackage-specific limits include 56 capsules/28 days (ORIAHNN) and 60 tablets/30 days for some antidiabetics (see product entries).
    inv-18: Quantity limits examples
    GI / PPI and sucralfate examplesPPI and related products commonly show QL = 60 capsules/30 days; sucralfate suspension shows PA, QL (1200 mL/30 days).
    Injectable/kit QL examplesExamples include 2 kits/28 days for some biologic starter kits (CIMZIA) and 540 packs/365 days for FOSRENOL powder packs.
    Capsule/tablet yearly limitsSome agents use yearly limits such as 1080 tablets/365 days for select renal agents; others use monthly/28‑day windows as noted per product.

    Provider Actions — Prior Authorization, Step Therapy, Documentation

    Prior Authorization

    Prior Authorization Required

    Prior Authorization (PA) may be required for many drugs across categories (antifungals, antivirals, HCV agents, specialty oncology agents, biologics, select specialty products, PA‑marked or PA‑designated drugs). When PA is required the prescriber must submit a prior authorization request and receive approval before the medication will be covered. Failure to obtain required PA, exceed quantity limits, or omit required PA/QL/SP documentation may result in denial of coverage and member financial liability.

    • PA applies to many specialty oncology agents (examples marked PA/QL/SP next to agent names in the Drug List).
    • Selected antifungals and other specialty antimicrobials are PA‑designated (e.g., BREXAFEMME = PA, CRESEMBA = PA).
    • Selected antivirals and HCV agents are subject to PA and QL (e.g., HARVONI = PA, MAVYRET = PA where noted).
    • PA is required for PA‑marked or PA‑designated drugs across the formulary; check the Special Requirements column for 'PA'.
    • Certain biologics and specialty drugs require PA and often have QL and SP (e.g., REPATHA = PA, QL; NUCALA = PA, QL, SP; FASENRA = PA, QL, SP).
    • TRYVIO is PA and has QL (TRYVIO: PA, QL 30 tablets/30 days).
    • Colesevelam oral suspension packets are PA and have QL (Colesevelam packet: PA, QL 30 packets/30 days).
    • REPATHA (evolocumab) requires PA and has quantity limits (6 syringes/pens per 28 days as listed).
    • Dispensed quantities beyond posted dispensing/quantity limits may be denied; members are responsible for full cost if provider dispenses beyond limits without coverage.
    • PA / Specialty Pharmacy (SP) / Quantity Limit (QL) triggers are indicated in the Drug List Special Requirements column (PA, SP, QL, ST, AC).
    • Noncompliance with QL or PA/SP requirements at claim submission may result in denial at point of adjudication.
    • PA, QL, or SP omissions on the prior authorization submission can trigger denial or delays — include required documentation.
    • Some formulations or routes have separate PA/QL requirements (e.g., oral solutions, packets, starter/therapy packs).
    • FUROSCIX, droxidopa and other specialty products have explicit PA/QL entries (FUROSCIX = PA, QL; droxidopa = PA, QL).
    • Specialty biologics and high-cost agents routinely have PA, QL and specialty pharmacy requirements and require supporting clinical documentation.
    • Selected specialty agents (e.g., PROCYSBI, FILSPARI, ALYFTREK) are PA‑flagged and have QL/SP designations.
    • Quantity limits are enforced and documented at claim; common QL examples are shown next to agent names (e.g., QL (30 tablets/30 days)).
    • Specialty pharmacy note: many SP-designated products must be dispensed via an approved specialty pharmacy as noted in the Drug List.
    • Vaccine entries include administrative coverage notes (AC) — providers should follow vaccine administrative coverage documentation and billing guidance.
    • PALFORZIA and similar products have specialty dispensing requirements (SP) — follow the Drug List for level-specific SP designations.
    • Providers or members must submit a Drug List exception (see Exception Process) when a drug is not on the Drug List; call the number on the member ID card.
    • PA submission expectations: submit clinical documentation supporting medical necessity, prior treatment history or step therapy trials when required, and any specialty pharmacy enrollment documentation.
    • NUCALA (mepolizumab) requires PA and QL with SP and has specific documentation requirements for coverage (dose/formulation distinction).

    Initiation & Initial Dispensing Controls

    Initiation controls for selected antidiabetics/GLP‑1s

    Utilization controls applicable at initiation for certain agents

    GLP1_initiation_controls: Selected antidiabetic and GLP‑1 agents require utilization controls at initiation: MOUNJARO (tirzepatide) formulations require prior authorization (PA) and have quantity limits (QL) — e.g., QL 4 pens/28 days or QL 4 pens/180 days depending on presentation; OZEMPIC (semaglutide) and RYBELSUS (semaglutide oral) are listed with PA and QL for some presentations.see product QL entries

    Providers must submit PA requests where indicated prior to initial dispensing

    Initial dispensing limits

    Quantity limits for initial dispensing where specified

    Initial_dispensing_QL_examples: Some products include initial dispensing quantity limits indicated in the Requirements/Limits field (examples: aprepitant capsule therapy pack QL 3 packs/30 days; EMEND oral suspension QL 9 kits/30 days; aprepitant 80 mg QL 6 capsules/30 days).per product QL

    These are formulary QL entries; specific clinical initiation criteria are not provided in these chunks.

    Step Therapy — Presence and Examples

    Product / ClassStep Therapy (ST) statusNotes
    Antivirals / HIV & HCV agents (e.g., HARVONI, ISENTRESS, MAVYRET, PAXLOVID)not_coveredNo explicit step-therapy sequences listed; products are managed via PA, QL, and SP flags (e.g., HARVONI = PA, QL 30 tablets/30 days, SP; ISENTRESS = QL 60/180 packets).
    ScopeStep Therapy (ST)Coverage controls
    General product listings where no explicit ST sequence providednot_coveredCoverage indicated by PA, QL, and SP flags rather than ordered step requirements; prescribers must follow PA/QL/SP as listed per product lines.
    Oncology / Specialty oncology agentsStep Therapy (ST) statusProvider action
    Multiple oral antineoplastics (e.g., abiraterone, ALECENSA, IBRANCE, others)neutralPrior authorization required for many oncology/specialty oral agents (Requirements/Limits include PA, QL, SP); explicit step-therapy sequences are not provided in the listing — PA must be obtained where indicated.
    Product groupsStep Therapy (ST)Management flags
    Assorted agents across extract (multiple classes)not_coveredNo explicit step therapy sequences captured; products show per-product PA and QL entries (e.g., IBRANCE = PA, QL 21 capsules/28 days, SP).
    Contraceptives / Related productsAdministrative Controls (AC) presentNotes
    Contraceptive products (e.g., ANNOVERA, AVERI, various OCPs)neutralSeveral contraceptives are labeled AC or AC + QL (e.g., ANNOVERA = AC QL 1 ring/365 days; other OCPs show AC and QL 28 tablets/21 days), indicating administrative coverage controls rather than explicit ST sequences.
    GLP‑1 / Weight‑management agentsStep Therapy (ST) statusUtilization controls
    GLP‑1 and weight-management agents (e.g., MOUNJARO, OZEMPIC, RYBELSUS)not_coveredPA is required for selected presentations (e.g., MOUNJARO = PA, QL 4 pens/28 days; OZEMPIC = PA, QL 1 pen/28 days or specified mL limits). No multi-step failure sequences are specified in the extract.
    KERENDIA (finerenone) / related agentsStep Therapy (ST) statusReference
    KERENDIA and selected products noted in listingcoveredKERENDIA is indicated with 'ST' in Requirements/Limits in the listing — prescribers should follow step therapy where ST is listed. (ST flags appear in product Requirements/Limits.)
    Various formulary entriesStep Therapy (ST) presenceRemarks
    Cardiovascular / miscellaneous (diltiazem, felodipine, nisoldipine, etc.)not_coveredNo explicit step-therapy sequences are specified in these chunks; products are listed with tiering and occasional PA/QL flags but not ordered ST steps.
    Pulmonary / Cardiology specialty agentsStep Therapy (ST) statusManagement
    Pulmonary/cardiology specialty agents (e.g., XOLAIR, ALYFTREK, REPATHA)not_coveredMany pulmonary and specialty cardiology drugs are designated SP and require PA/QL (e.g., XOLAIR = PA, SP; ALYFTREK = PA, QL, SP; REPATHA = PA, QL). No explicit step-therapy failure sequences are provided in the listing.
    General observationStep Therapy (ST) implicationPlan
    Overall extract coveragenot_coveredThe document generally lacks explicit step-therapy algorithms; coverage and utilization management are implemented via per-product PA, QL, SP, and occasional ST flags. Providers must follow the Requirements/Limits shown for each product.
    Programmatic controls (SP/PA)Step Therapy (ST) inferenceNotes
    Products marked SP/PA across listingneutralSP and PA designations imply specialty program management and prior-approval requirements but do not specify an ordered step-failure requirement; such program controls may functionally act as utilization management without explicit ST sequences.
    Antidepressants / Related agentsStep Therapy (ST) statusExample entries
    Selected antidepressants and related products (e.g., AUVELITY, citalopram, FETZIMA, TRINTELLIX)coveredSeveral antidepressants are designated 'ST' in Requirements/Limits (e.g., AUVELITY = ST; citalopram = QL 30/30 days, ST; FETZIMA = ST; TRINTELLIX = ST), indicating step therapy policies apply where noted.
    Prescriber responsibilityWhen ST is listedAction required
    Products flagged with 'ST' in Requirements/Limits (various classes)coveredWhen a product listing includes 'ST', the prescriber must follow the step therapy requirement indicated in the product's Requirements/Limits; the source lists ST flags for several products but does not provide detailed prior-failure sequences in the extract.

    Quantity Limits — Product Examples

    inv-138: azithromycin tablets (250 mg; 500 mg) — QL 60
    Quantity limit60 tablets/180 days
    Formulation/strengthAzithromycin tablets available 250 mg and 500 mg
    Source noteListed as QL (60 tablets/180 days) in the drug list entry for azithromycin tablets
    inv-139: clarithromycin ER 500 mg — QL 28
    Quantity limit28 tablets/30 days
    ProductClarithromycin ER 500 mg (extended‑release 24 hr)
    Drug list entryRequirements/Limits = QL (28 tablets/30 days)
    inv-140: ARIKAYCE (amikacin liposome inhalation) — QL 235.2
    Quantity limit235.2 mL per 28 days
    ProductARIKAYCE (amikacin liposome inhalation) 590 mg/8.4 mL suspension
    FlagsListed with QL (235.2 mls/28 days) and SP PA in the drug list
    inv-141: KITABIS PAK — QL 56
    Quantity limit56 containers/56 days
    ProductKITABIS PAK (tobramycin nebulizer solution 300 mg/mL)
    FlagsRequirements/Limits = QL (56 containers/56 days), SP PA noted for nebulized tobramycin formulations
    inv-142: TOBI PODHALER — QL 224
    Quantity limit224 capsules/56 days
    ProductTOBI PODHALER (tobramycin inhalation capsules 28 mg)
    FlagsEntry shows QL (224 capsules/56 days) and SP designation
    inv-143: many antiretroviral agents — QL 30
    Quantity limit30 tablets/30 days
    ScopeMany antiretroviral (ARV) agents listed with QL = 30 tablets/30 days (examples: GENVOYA, DOVATO, JULUCA).
    Associated flagsARV entries commonly include SP or PA as indicated per product
    inv-144: EPCLUSA — QL 30
    Quantity limit30 tablets/30 days
    ProductEPCLUSA (sofosbuvir‑velpatasvir)
    FlagsListed with PA, QL (30 tablets/30 days), SP for pellet/ tablet presentations
    inv-145: HARVONI — QL 30
    Quantity limit30 tablets/month
    ProductHARVONI (ledipasvir‑sofosbuvir)
    FlagsEntry indicates PA, QL (30 tablets/30 days), SP for some presentations
    inv-146: JULUCA — QL 30
    Quantity limit30 tablets/30 days
    ProductJULUCA (dolutegravir‑rilpivirine) 50‑25 mg tab
    Drug list entryRequirements/Limits = QL (30 tablets/30 days)
    inv-147: SUNLENCA therapy pack — QL 4
    Quantity limit4 therapy packs/year
    ProductSUNLENCA (lenacapavir) therapy pack — therapy pack count limited (4 packs/365 days)
    NoteListed as QL (4 tablets/365 days) for therapy pack formulations
    inv-148: PAXLOVID packs — QL 11
    Quantity limit11 tablets/30 days (example pack)
    ProductPAXLOVID (nirmatrelvir/ritonavir) pack configurations shown with QL per pack
    ExamplesEntry lists QL (11 tablets/30 days) for a 6×150 mg + 5×100 mg pack; other pack sizes have different QLs
    inv-149: XIFAXAN 550 mg — QL 126
    Quantity limit126 tablets/365 days
    ProductXIFAXAN (rifaximin) 550 mg tablets
    Drug list entryRequirements/Limits = QL (126 tablets/365 days)
    inv-150: abiraterone 250 mg — QL 120 tablets/30 days
    Quantity limit120 tablets/30 days
    ProductAbiraterone acetate 250 mg tablets
    FlagsRequirements/Limits = PA, QL (120 tablets/30 days), SP listed for abiraterone 250 mg
    inv-151: abiraterone 500 mg — QL 60 tablets/30 days
    Quantity limit60 tablets/30 days
    ProductAbiraterone acetate 500 mg tablets
    FlagsRequirements/Limits = PA, QL (60 tablets/30 days), SP
    inv-152: ALECENSA 150 mg — QL 240 capsules/30 days
    Quantity limit240 capsules/30 days
    ProductALECENSA (alectinib) 150 mg capsules
    FlagsRequirements/Limits = PA, QL (240 capsules/30 days), SP
    inv-153: BOSULIF 100 mg — QL 150 capsules/30 days
    Quantity limit150 capsules/30 days
    ProductBOSULIF (bosutinib) 100 mg capsules
    FlagsRequirements/Limits = PA, QL (150 capsules/30 days), SP noted for some strengths
    inv-154: ERIVEDGE 150 mg — 30 capsules
    Quantity limit30 capsules (30 days)
    ProductERIVEDGE (vismodegib) 150 mg capsules
    Drug list entryRequirements/Limits = PA, QL (30 capsules/30 days), SP
    inv-155: IBRANCE palbociclib — 21 capsules
    Quantity limit21 capsules/28 days
    ProductIBRANCE (palbociclib) various strengths
    Drug list entryRequirements/Limits = PA, QL (21 capsules/28 days), SP
    inv-156: LUMAKRAS 120 mg — 240 tablets
    Quantity limit240 tablets/30 days
    ProductLUMAKRAS (sotorasib) 120 mg tablets
    FlagsRequirements/Limits = PA, QL (240 tablets/30 days), SP
    inv-157: STIVARGA 40 mg — 84 tablets
    Quantity limit84 tablets/28 days
    ProductSTIVARGA (regorafenib) 40 mg tablets
    FlagsRequirements/Limits = QL (84 tablets/28 days), SP, PA in some entries
    inv-158: TAGRISSO — 30 tablets
    Quantity limit30 tablets/30 days
    ProductTAGRISSO (osimertinib) 40/80 mg tablets
    Drug list entryRequirements/Limits = PA, QL (30 tablets/30 days), SP
    inv-159: sunitinib 12.5 mg — 90 capsules
    Quantity limit90 capsules/30 days
    ProductSunitinib 12.5 mg capsules (Sutent)
    Drug list entryRequirements/Limits = PA, QL (90 capsules/30 days), SP
    inv-160: TABRECTA 150/200 mg — 120 tablets
    Quantity limit120 tablets/30 days
    ProductTABRECTA (capmatinib) 150/200 mg tablets
    FlagsRequirements/Limits = QL (120 tablets/30 days), SP PA indicated
    inv-161: TAFINLAR — 120 capsules
    Quantity limit120 capsules/30 days
    ProductTAFINLAR (dabrafenib) 50/75 mg capsules
    Drug list entryRequirements/Limits = PA, QL (120 capsules/30 days), SP
    inv-162: VENCLEXTA 10 mg — 60 tablets
    Quantity limit60 tablets/30 days
    ProductVENCLEXTA 10 mg tablets
    Drug list entryRequirements/Limits = QL (60 tablets/30 days), SP PA noted
    inv-163: VENCLEXTA 100 mg — 180 tablets
    Quantity limit180 tablets/30 days
    ProductVENCLEXTA 100 mg tablets
    Drug list entryRequirements/Limits = QL (180 tablets/30 days), SP PA noted
    inv-164: ZEJULA — 30 tablets
    Quantity limit30 tablets/30 days
    ProductZEJULA (niraparib) 100/200/300 mg tablets
    Drug list entryRequirements/Limits = PA, QL (30 tablets/30 days), SP
    inv-165: prednisolone oral soln 15 mg/mL — 900 mL
    Quantity limit900 mL/30 days
    ProductPrednisolone oral solution 15 mg/mL
    Drug list entryRequirements/Limits noted in drug list; QL = 900 mL/30 days for this concentration
    inv-166: prednisolone oral soln 20 mg/mL — 450 mL
    Quantity limit450 mL/30 days
    ProductPrednisolone oral solution 20 mg/mL
    Drug list entryRequirements/Limits show QL = 450 mL/30 days for this concentration
    inv-167: Multiple QL examples (contraceptives, patches, pens, rings)
    Contraceptives and device examplesMultiple contraceptive forms show QL: 28 tablets/21 days (most OCPs), 3 patches/21 days (patch), 1 ring/365 days (ANNOVERA/NUVARING).
    Pen and pack examplesGLP‑1 pens and weight‑management pens show QL values by package (e.g., 4 pens/28 days or 4 pens/180 days, 8 pens/180 days).
    Administration formsDevice and pack-based QLs apply to rings, patches, pens, and therapy packs as listed per product lines.
    inv-168: GALAFOLD — QL 14
    Quantity limit14 capsules/28 days
    ProductGALAFOLD (migalastat) 123 mg capsules
    Drug list entryRequirements/Limits = PA, QL (14 capsules/28 days), SP
    inv-169: FOLLISTIM AQ — QL 15 cartridges
    Quantity limit15 cartridges/30 days
    ProductFOLLISTIM AQ follitropin beta injection 300 unit/0.36 mL cartridges
    FlagsRequirements/Limits = QL (15 cartridges/30 days), SP indicated for fertility products
    inv-170: JYNARQUE therapy pack — QL 56
    Quantity limit56 tablets/28 days
    ProductJYNARQUE (tolvaptan) therapy pack
    Drug list entryRequirements/Limits = PA, QL (56 tablets/28 days), SP for certain pack presentations
    inv-171: SOMAVERT — QL 30 vials
    Quantity limit30 vials/30 days
    ProductSOMAVERT (pegvisomant) for injection
    FlagsRequirements/Limits = QL (30 vials/30 days), SP noted
    inv-172: SKYTROFA various cartridges — QL (see listing)
    Quantity listingVarious cartridge limits provided per SKYTROFA strength (see drug list entries)
    ProductSKYTROFA lonapegsomatropin cartridges — multiple cartridge sizes/strengths are listed with PA, SP annotations
    NoteConsult product lines for exact per-strength QL values as listed in the formulary
    inv-173: NORLIQVA oral solution — QL 300 mL
    Quantity limit300 mL/30 days
    ProductNORLIQVA (amlodipine oral solution)
    Drug list entryRequirements/Limits = PA, QL (300 mL/30 days)
    inv-174: TRYVIO 12.5 mg — QL 30 tablets
    Quantity limit30 tablets/30 days
    ProductTRYVIO (aprocitentan) 12.5 mg tablets
    Drug list entryRequirements/Limits = PA, QL (30 tablets/30 days), SP
    inv-175: FUROSCIX — QL 8 kits
    Quantity limit8 kits/180 days
    ProductFUROSCIX (furosemide subcutaneous cartridge kit 80 mg/10 mL)
    Drug list entryRequirements/Limits = PA, QL (8 kits/180 days)
    inv-176: droxidopa capsule-specific limits
    Quantity limits by strengthDroxidopa capsule-specific limits: 100 mg = 450 capsules/30 days; 200 mg & 300 mg = 180 capsules/30 days
    ProductDroxidopa (Northera) capsules
    FlagsEntries show PA and QL per strength in the drug list
    inv-177: QBRELIS lisinopril oral solution — QL 2400 mL
    Quantity limit2400 mL/30 days
    ProductQBRELIS lisinopril oral solution
    Drug list entryRequirements/Limits = PA, QL (2400 mL/30 days)
    inv-178: enalapril oral solution (Epaned) — QL 1200 mL
    Quantity limit1200 mL/30 days
    ProductEnalapril maleate oral solution (Epaned)
    Drug list entryRequirements/Limits = PA, QL (1200 mL/30 days)
    inv-179: droxidopa 100 mg — QL 450 capsules
    Quantity limit450 capsules/30 days
    ProductDroxidopa 100 mg capsules (Northera)
    Drug list entryRequirements/Limits = PA, QL (450 capsules/30 days)
    inv-180: droxidopa 200/300 mg — QL 180 capsules
    Quantity limit180 capsules/30 days
    ProductDroxidopa 200 mg and 300 mg capsules (Northera)
    Drug list entryRequirements/Limits = PA, QL (180 capsules/30 days)
    inv-181: colesevelam packet (Welchol) — QL 30 packets
    Quantity limit30 packets/30 days
    ProductColesevelam HCl packets for suspension (Welchol) 3.75 g
    Drug list entryRequirements/Limits = PA, QL (30 packets/30 days)
    inv-182: fenofibrate 120 mg — QL 30 tablets
    Quantity limit30 tablets/30 days
    ProductFenofibrate 120 mg (Fenoglide)
    Drug list entryRequirements/Limits = QL (30 tablets/30 days)
    inv-183: REPATHA prefilled syringe — QL 6 syringes
    Quantity limit6 syringes/28 days
    ProductREPATHA (evolocumab) prefilled syringe 140 mg/mL
    Drug list entryRequirements/Limits = PA, QL (6 syringes/28 days)
    inv-184: REPATHA SURECLICK — QL 6 pens
    Quantity limit6 pens/28 days
    ProductREPATHA SURECLICK auto‑injector 140 mg/mL
    Drug list entryRequirements/Limits = PA, QL (6 pens/28 days)
    inv-185: UPTRAVI — QL 60 tablets
    Quantity limit60 tablets/30 days
    ProductUPTRAVI (selexipag)
    Drug list entryRequirements/Limits = PA, QL (60 tablets/30 days), SP
    inv-186: VYNDAMAX — QL 30 capsules
    Quantity limit30 capsules/30 days
    ProductVYNDAMAX (tafamidis) 61 mg capsules
    Drug list entryRequirements/Limits = QL (30 capsules/30 days), SP PA noted
    inv-187: VYNDAQEL — QL 120 capsules
    Quantity limit120 capsules/30 days
    ProductVYNDAQEL (tafamidis meglumine) 20 mg capsules
    Drug list entryRequirements/Limits = PA, QL (120 capsules/30 days), SP
    inv-188: avanafil (Stendra) — QL 8 tablets
    Quantity limit8 tablets/30 days
    ProductAvanafil (Stendra) tablets
    Drug list entryRequirements/Limits = QL (8 tablets/30 days)
    inv-189: sildenafil (Viagra) — QL 8 tablets
    Quantity limit8 tablets/30 days
    ProductSildenafil (Viagra) tablets
    Drug list entryRequirements/Limits = QL (8 tablets/30 days)
    inv-190: tadalafil 2.5/5 mg — QL 30 tablets
    Quantity limit30 tablets/30 days
    ProductTadalafil 2.5 mg / 5 mg (Cialis) tablets
    Drug list entryRequirements/Limits = QL (30 tablets/30 days)
    inv-191: TYVASO DPI maintenance cartridges — QL 112 cartridges
    Quantity limit112 cartridges/28 days
    ProductTYVASO DPI maintenance cartridges (treprostinil)
    Drug list entryRequirements/Limits = QL (112 cartridges/28 days), SP PA for some kits
    inv-192: TYVASO DPI titration kit — QL 252 cartridges
    Quantity limit252 cartridges/180 days
    ProductTYVASO DPI titration kit (treprostinil)
    Drug list entryRequirements/Limits = PA, QL (252 cartridges/180 days), SP
    inv-193: ADVAIR HFA inhaler — QL inhaler/30 days
    Inhaler limitsADVAIR HFA: inhaler/30 days; Albuterol HFA: 2 inhalers/30 days
    Respiratory biologic examplesFASENRA PEN listed with PA, QL (1 pen/28 days) and SP; NUCALA listed with PA, QL (3 mL/28 days or 1 syringe/28 days).
    Dispensing enforcementInhaler and biologic cartridge/syringe limits enforced at claim per product lines
    inv-195: FASENRA PEN — QL 1 pen/28 days
    Quantity limit1 pen/28 days (FASENRA PEN)
    ProductFASENRA PEN (benralizumab) 30 mg/mL auto‑injector
    Drug list entryRequirements/Limits = PA, QL (1 pen/28 days), SP
    inv-196: NUCALA various presentations — QL 3 ml/28 days or 1 syringe/28 days
    Quantity limit3 mL/28 days (pen) or 1 syringe/28 days (syringe)
    ProductNUCALA (mepolizumab) various presentations
    FlagsRequirements/Limits = PA, QL (3 mL/28 days) or PA, QL (1 syringe/28 days), SP for certain presentations
    inv-197: TRIKAFTA granules/packets — QL 56 packets/28 days
    Quantity limit56 packets/28 days
    ProductTRIKAFTA (elexacaftor‑tezacaftor‑ivacaftor) granules/packets
    Drug list entryRequirements/Limits = PA, QL (56 packets/28 days), SP
    inv-198: lansoprazole — QL 60 capsules/30 days
    Quantity limit60 capsules/30 days
    ProductLansoprazole / Omeprazole delayed‑release formulations
    Drug list entryEntries show QL (60 capsules/30 days) for lansoprazole and omeprazole formulations
    inv-201: sucralfate suspension — PA, QL 1200 mL/30 days
    Quantity limitPA, QL (1200 mL/30 days)
    ProductSucralfate suspension 1 g/mL (Carafate)
    Drug list entryRequirements/Limits = PA, QL (1200 mLs/30 days)
    inv-202: CIMZIA / FOSRENOL — QL examples
    Quantity limitPA, QL (2 kits/28 days) — CIMZIA; QL (540 packs/365 days) — FOSRENOL
    ProductsCIMZIA certolizumab pegol starter/kit and FOSRENOL lanthanum carbonate powder packs
    FlagsCIMZIA listed with PA, QL (2 kits/28 days), SP; FOSRENOL listed with QL (540 packs/365 days)
    inv-204: TRULANCE / VOWST — QL examples
    Quantity limit30 tablets/30 days (TRULANCE) and PA, QL (12 capsules/12 months) for VOWST
    ProductsTRULANCE plecanatide 3 mg; VOWST fecal microbiota capsules
    Drug list entryTRULANCE = QL (30 tablets/30 days); VOWST = PA, QL (12 capsules/12 months)
    inv-167: Multiple (see entries)
    Multiple QL examples summarySee individual drug entries for exact QL by product — examples across the formulary include tablet/capsule limits per 30/28/365‑day windows, inhaler counts per 30 days, pen/kit counts per 28/180 days, and mL limits for oral solutions/suspensions.
    Actionable guidanceWhen prescribing, confirm the product‑specific QL and any PA/SP flags in the formulary to avoid claim denial or member charge for excess quantity.
    Where to confirmRefer to the Drug List entries (Requirements/Limits column) shown in the formulary for the precise QL for each formulation/packaging.
    inv-206: clozapine ODT / psychotropic QL examples
    Psychotropic QL examplesClozapine ODT and Versacloz suspension have multi-strength QLs (e.g., 90/270/120 tablets/30 days); aripiprazole oral solution QL (900 mL/30 days); lurasidone QL varies by strength (30 or 60 tablets/30 days).
    Common QL valuesMany antipsychotics and antidepressants show typical QL = 30 tablets/30 days or strength‑dependent 60 tablets/30 days limits.
    ST/QL intersectionSome psychotropic entries also include ST (step therapy) flags in Requirements/Limits alongside QL values.
    inv-217: Weight‑management pens — QL examples
    SAXENDA QL15 mL/30 days
    WEGOVY QL options8 pens/180 days or 4 pens/28 days depending on package
    ZEPBOUND QL options4 pens/180 days or 4 pens/28 days depending on strength
    inv-220: AVONEX / BETASERON / Gilenya — QL examples
    Interferon / MS agentsAVONEX / AVONEX PEN: kit/28 days; BETASERON: 14 vials/28 days
    Fingolimod QLGilenya (fingolimod) 0.5 mg: 30 capsules/30 days
    FlagsThese specialty/infusion‑related products include PA and SP designations where noted

    Site of Care & Specialty Pharmacy

    Note
    Note
    Note
    Note
    Note
    Note
    Note

    Definitions & Notation

    Background & Scope

    Specialty drugs are handled differently from standard retail medications: they may be oral, topical, or injectable and can be either self‑administered or provider‑administered. Provider‑administered products may fall under the medical benefit rather than the pharmacy benefit. The plan selects drugs for the list based on committee review considering safety, efficacy, cost, and FDA regulation. For specialty products the formulary uses annotations such as SP (specialty pharmacy), PA (prior authorization), and QL (quantity limits) to indicate additional management, and some specialty products will require dispensing through a specialty pharmacy or infusion/clinic setting as indicated.